Acupuncture therapy for the symptoms of Parkinson's disease.
Identifieur interne : 003C01 ( PubMed/Checkpoint ); précédent : 003C00; suivant : 003C02Acupuncture therapy for the symptoms of Parkinson's disease.
Auteurs : Lisa M. Shulman [États-Unis] ; X. Wen ; William J. Weiner ; Dinorah Bateman ; Alireza Minagar ; Robert Duncan ; Janet KonefalSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- Activities of Daily Living (classification), Acupuncture Points, Acupuncture Therapy, Aged, Antiparkinson Agents (administration & dosage), Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neurologic Examination, Parkinson Disease (diagnosis), Parkinson Disease (therapy), Pilot Projects, Quality of Life, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents.
- classification : Activities of Daily Living.
- diagnosis : Parkinson Disease.
- therapy : Parkinson Disease.
- Acupuncture Points, Acupuncture Therapy, Aged, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neurologic Examination, Pilot Projects, Quality of Life, Treatment Outcome.
Abstract
Interest in alternative medical treatments, including acupuncture, is increasing. Alternative treatments must be subjected to the same objective standards as all medical treatments. A non-blinded pilot study of the safety, tolerability, and efficacy of acupuncture (ACUPX) for the symptoms of (PD) was performed. Twenty PD patients (mean age, 68 years; disease duration, 8.5 years; Hoehn and Yahr [H&Y] stage, 2.2; Unified Parkinson's Disease Rating Scale score [UPDRS], 38.7) each received acupuncture treatments by a licensed acupuncturist. All patients were treated with two acupuncture treatment sessions per week. The first seven patients received 10 treatments and the last 13 patients 16 treatments. Patients were evaluated before and after ACUPX with the Sickness Impact Profile (SIP); UPDRS; H & Y; Schwab and England (S & E); Beck Anxiety Inventory (BAI); Beck Depression Inventory (BDI); quantitative motor tests, including timed evaluations of arm pronation supination movements, finger dexterity, finger movements between two fixed measured points, and the stand-walk-sit test; and a patient questionnaire designed for the study. Following ACUPX, there were no significant changes in the UPDRS, H&Y, S&E, BAI, BDI, quantitative motor tests, total SIP or the two SIP Dimension scores. Analysis of the 12 SIP categories not corrected for multiple comparisons revealed a post-ACUPX improvement in the sleep and rest category only (P = 0.03). On the patient questionnaire, 85% of patients reported subjective improvement of individual symptoms including tremor, walking, handwriting, slowness, pain, sleep, depression, and anxiety. There were no adverse effects. ACUPX therapy is safe and well tolerated in PD patients. A range of PD and behavioral scales failed to show improvement following ACUPX other than sleep benefit, although patients reported other discrete symptomatic improvements. A broad battery of tests in PD patients suggested that ACUPX resulted in improvement of sleep and rest only. This finding needs to be verified using more in-depth and controlled evaluation of ACUPX for PD-related sleep disturbance.
DOI: 10.1002/mds.10134
PubMed: 12210879
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:12210879Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Acupuncture therapy for the symptoms of Parkinson's disease.</title><author><name sortKey="Shulman, Lisa M" sort="Shulman, Lisa M" uniqKey="Shulman L" first="Lisa M" last="Shulman">Lisa M. Shulman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. lshulman@som.umaryland.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland 21201</wicri:regionArea><wicri:noRegion>Maryland 21201</wicri:noRegion></affiliation></author><author><name sortKey="Wen, X" sort="Wen, X" uniqKey="Wen X" first="X" last="Wen">X. Wen</name></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J" last="Weiner">William J. Weiner</name></author><author><name sortKey="Bateman, Dinorah" sort="Bateman, Dinorah" uniqKey="Bateman D" first="Dinorah" last="Bateman">Dinorah Bateman</name></author><author><name sortKey="Minagar, Alireza" sort="Minagar, Alireza" uniqKey="Minagar A" first="Alireza" last="Minagar">Alireza Minagar</name></author><author><name sortKey="Duncan, Robert" sort="Duncan, Robert" uniqKey="Duncan R" first="Robert" last="Duncan">Robert Duncan</name></author><author><name sortKey="Konefal, Janet" sort="Konefal, Janet" uniqKey="Konefal J" first="Janet" last="Konefal">Janet Konefal</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2002">2002</date><idno type="RBID">pubmed:12210879</idno><idno type="pmid">12210879</idno><idno type="doi">10.1002/mds.10134</idno><idno type="wicri:Area/PubMed/Corpus">003A07</idno><idno type="wicri:Area/PubMed/Curation">003A07</idno><idno type="wicri:Area/PubMed/Checkpoint">003C01</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Acupuncture therapy for the symptoms of Parkinson's disease.</title><author><name sortKey="Shulman, Lisa M" sort="Shulman, Lisa M" uniqKey="Shulman L" first="Lisa M" last="Shulman">Lisa M. Shulman</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. lshulman@som.umaryland.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland 21201</wicri:regionArea><wicri:noRegion>Maryland 21201</wicri:noRegion></affiliation></author><author><name sortKey="Wen, X" sort="Wen, X" uniqKey="Wen X" first="X" last="Wen">X. Wen</name></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J" last="Weiner">William J. Weiner</name></author><author><name sortKey="Bateman, Dinorah" sort="Bateman, Dinorah" uniqKey="Bateman D" first="Dinorah" last="Bateman">Dinorah Bateman</name></author><author><name sortKey="Minagar, Alireza" sort="Minagar, Alireza" uniqKey="Minagar A" first="Alireza" last="Minagar">Alireza Minagar</name></author><author><name sortKey="Duncan, Robert" sort="Duncan, Robert" uniqKey="Duncan R" first="Robert" last="Duncan">Robert Duncan</name></author><author><name sortKey="Konefal, Janet" sort="Konefal, Janet" uniqKey="Konefal J" first="Janet" last="Konefal">Janet Konefal</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2002" type="published">2002</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Activities of Daily Living (classification)</term><term>Acupuncture Points</term><term>Acupuncture Therapy</term><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (therapy)</term><term>Pilot Projects</term><term>Quality of Life</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Activities of Daily Living</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Acupuncture Points</term><term>Acupuncture Therapy</term><term>Aged</term><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination</term><term>Pilot Projects</term><term>Quality of Life</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interest in alternative medical treatments, including acupuncture, is increasing. Alternative treatments must be subjected to the same objective standards as all medical treatments. A non-blinded pilot study of the safety, tolerability, and efficacy of acupuncture (ACUPX) for the symptoms of (PD) was performed. Twenty PD patients (mean age, 68 years; disease duration, 8.5 years; Hoehn and Yahr [H&Y] stage, 2.2; Unified Parkinson's Disease Rating Scale score [UPDRS], 38.7) each received acupuncture treatments by a licensed acupuncturist. All patients were treated with two acupuncture treatment sessions per week. The first seven patients received 10 treatments and the last 13 patients 16 treatments. Patients were evaluated before and after ACUPX with the Sickness Impact Profile (SIP); UPDRS; H & Y; Schwab and England (S & E); Beck Anxiety Inventory (BAI); Beck Depression Inventory (BDI); quantitative motor tests, including timed evaluations of arm pronation supination movements, finger dexterity, finger movements between two fixed measured points, and the stand-walk-sit test; and a patient questionnaire designed for the study. Following ACUPX, there were no significant changes in the UPDRS, H&Y, S&E, BAI, BDI, quantitative motor tests, total SIP or the two SIP Dimension scores. Analysis of the 12 SIP categories not corrected for multiple comparisons revealed a post-ACUPX improvement in the sleep and rest category only (P = 0.03). On the patient questionnaire, 85% of patients reported subjective improvement of individual symptoms including tremor, walking, handwriting, slowness, pain, sleep, depression, and anxiety. There were no adverse effects. ACUPX therapy is safe and well tolerated in PD patients. A range of PD and behavioral scales failed to show improvement following ACUPX other than sleep benefit, although patients reported other discrete symptomatic improvements. A broad battery of tests in PD patients suggested that ACUPX resulted in improvement of sleep and rest only. This finding needs to be verified using more in-depth and controlled evaluation of ACUPX for PD-related sleep disturbance.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">12210879</PMID><DateCreated><Year>2002</Year><Month>09</Month><Day>04</Day></DateCreated><DateCompleted><Year>2002</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>4</Issue><PubDate><Year>2002</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Acupuncture therapy for the symptoms of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>799-802</MedlinePgn></Pagination><Abstract><AbstractText>Interest in alternative medical treatments, including acupuncture, is increasing. Alternative treatments must be subjected to the same objective standards as all medical treatments. A non-blinded pilot study of the safety, tolerability, and efficacy of acupuncture (ACUPX) for the symptoms of (PD) was performed. Twenty PD patients (mean age, 68 years; disease duration, 8.5 years; Hoehn and Yahr [H&Y] stage, 2.2; Unified Parkinson's Disease Rating Scale score [UPDRS], 38.7) each received acupuncture treatments by a licensed acupuncturist. All patients were treated with two acupuncture treatment sessions per week. The first seven patients received 10 treatments and the last 13 patients 16 treatments. Patients were evaluated before and after ACUPX with the Sickness Impact Profile (SIP); UPDRS; H & Y; Schwab and England (S & E); Beck Anxiety Inventory (BAI); Beck Depression Inventory (BDI); quantitative motor tests, including timed evaluations of arm pronation supination movements, finger dexterity, finger movements between two fixed measured points, and the stand-walk-sit test; and a patient questionnaire designed for the study. Following ACUPX, there were no significant changes in the UPDRS, H&Y, S&E, BAI, BDI, quantitative motor tests, total SIP or the two SIP Dimension scores. Analysis of the 12 SIP categories not corrected for multiple comparisons revealed a post-ACUPX improvement in the sleep and rest category only (P = 0.03). On the patient questionnaire, 85% of patients reported subjective improvement of individual symptoms including tremor, walking, handwriting, slowness, pain, sleep, depression, and anxiety. There were no adverse effects. ACUPX therapy is safe and well tolerated in PD patients. A range of PD and behavioral scales failed to show improvement following ACUPX other than sleep benefit, although patients reported other discrete symptomatic improvements. A broad battery of tests in PD patients suggested that ACUPX resulted in improvement of sleep and rest only. This finding needs to be verified using more in-depth and controlled evaluation of ACUPX for PD-related sleep disturbance.</AbstractText><CopyrightInformation>Copyright 2002 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. lshulman@som.umaryland.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Dinorah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Minagar</LastName><ForeName>Alireza</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Duncan</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Konefal</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000203">Activities of Daily Living</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015669">Acupuncture Points</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015670">Acupuncture Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>9</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>9</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12210879</ArticleId><ArticleId IdType="doi">10.1002/mds.10134</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Bateman, Dinorah" sort="Bateman, Dinorah" uniqKey="Bateman D" first="Dinorah" last="Bateman">Dinorah Bateman</name><name sortKey="Duncan, Robert" sort="Duncan, Robert" uniqKey="Duncan R" first="Robert" last="Duncan">Robert Duncan</name><name sortKey="Konefal, Janet" sort="Konefal, Janet" uniqKey="Konefal J" first="Janet" last="Konefal">Janet Konefal</name><name sortKey="Minagar, Alireza" sort="Minagar, Alireza" uniqKey="Minagar A" first="Alireza" last="Minagar">Alireza Minagar</name><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J" last="Weiner">William J. Weiner</name><name sortKey="Wen, X" sort="Wen, X" uniqKey="Wen X" first="X" last="Wen">X. Wen</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Shulman, Lisa M" sort="Shulman, Lisa M" uniqKey="Shulman L" first="Lisa M" last="Shulman">Lisa M. Shulman</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C01 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003C01 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:12210879
|texte= Acupuncture therapy for the symptoms of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:12210879" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |